276 related articles for article (PubMed ID: 21777949)
41. Decreased RECK and Increased EMMPRIN expression in urothelial carcinoma of the bladder are associated with tumor aggressiveness.
Wittschieber D; Stenzinger A; Klauschen F; Stephan C; Jung K; Erbersdobler A; Rabien A
Pathobiology; 2011; 78(3):123-31. PubMed ID: 21613799
[TBL] [Abstract][Full Text] [Related]
42. [Molecular changes in development and progression of urothelial carcinoma].
Hartmann A
Verh Dtsch Ges Pathol; 2003; 87():172-84. PubMed ID: 16888910
[TBL] [Abstract][Full Text] [Related]
43. Urothelial dysplasia and other flat lesions of the urinary bladder: clinicopathologic and molecular features.
Hodges KB; Lopez-Beltran A; Davidson DD; Montironi R; Cheng L
Hum Pathol; 2010 Feb; 41(2):155-62. PubMed ID: 19762067
[TBL] [Abstract][Full Text] [Related]
44. Clinical significance of denuded urothelium in bladder biopsy.
Levi AW; Potter SR; Schoenberg MP; Epstein JI
J Urol; 2001 Aug; 166(2):457-60. PubMed ID: 11458047
[TBL] [Abstract][Full Text] [Related]
45. Micropapillary urothelial carcinoma of the urinary bladder: a clinicopathological analysis of 24 cases.
Edgerton N; Sirintrapun SJ; Munoz M; Chen Z; Osunkoya AO
Int J Urol; 2011 Jan; 18(1):49-54. PubMed ID: 21114685
[TBL] [Abstract][Full Text] [Related]
46. Benign and low-grade papillary lesions of the urinary bladder: a review of the papilloma-papillary carcinoma controversy, and a report of five typical papillomas.
Eble JN; Young RH
Semin Diagn Pathol; 1989 Nov; 6(4):351-71. PubMed ID: 2692107
[TBL] [Abstract][Full Text] [Related]
47. Motility-related protein 1 (MRP-1/CD9) expression in urothelial bladder carcinoma and its relation to tumor recurrence and progression.
Mhawech P; Herrmann F; Coassin M; Guillou L; Iselin CE
Cancer; 2003 Oct; 98(8):1649-57. PubMed ID: 14534881
[TBL] [Abstract][Full Text] [Related]
48. Reduced immunohistochemical PTEN staining is associated with higher progression rate and recurrence episodes in non-invasive low-grade papillary urothelial carcinoma of the bladder.
Kulac I; Arslankoz S; Netto GJ; Ertoy Baydar D
Virchows Arch; 2018 Jun; 472(6):969-974. PubMed ID: 29368083
[TBL] [Abstract][Full Text] [Related]
49. Management of low grade papillary bladder tumors.
Herr HW; Donat SM; Reuter VE
J Urol; 2007 Oct; 178(4 Pt 1):1201-5; discussion 1205. PubMed ID: 17698090
[TBL] [Abstract][Full Text] [Related]
50. Non-invasive papillary urothelial neoplasms: the 2004 WHO/ISUP classification system.
Miyamoto H; Miller JS; Fajardo DA; Lee TK; Netto GJ; Epstein JI
Pathol Int; 2010 Jan; 60(1):1-8. PubMed ID: 20055945
[TBL] [Abstract][Full Text] [Related]
51. Utility of ProEx C in the histologic evaluation of the neoplastic and nonneoplastic urothelial lesions.
Moatamed NA; Vergara-Lluri ME; Lu D; Apple SK; Kerkoutian S; Rao JY
Hum Pathol; 2013 Nov; 44(11):2509-17. PubMed ID: 24029711
[TBL] [Abstract][Full Text] [Related]
52. Papillary urothelial hyperplasia: relationship to urothelial neoplasms.
Readal N; Epstein JI
Pathology; 2010 Jun; 42(4):360-3. PubMed ID: 20438409
[TBL] [Abstract][Full Text] [Related]
53. Urothelial cancer of bladder in young versus older adults: clinical and pathological characteristics and outcomes.
Telli O; Sarici H; Ozgur BC; Doluoglu OG; Sunay MM; Bozkurt S; Eroglu M
Kaohsiung J Med Sci; 2014 Sep; 30(9):466-70. PubMed ID: 25224770
[TBL] [Abstract][Full Text] [Related]
54. Histopathological evaluation of urothelial carcinomas in transurethral resection urinary bladder tumor specimens: eight years of single center experience.
Koyuncuer A
Asian Pac J Cancer Prev; 2015; 16(7):2871-7. PubMed ID: 25854375
[TBL] [Abstract][Full Text] [Related]
55. Conservative management of low risk superficial bladder tumors.
Pruthi RS; Baldwin N; Bhalani V; Wallen EM
J Urol; 2008 Jan; 179(1):87-90; discussion 90. PubMed ID: 17997444
[TBL] [Abstract][Full Text] [Related]
56. Urothelial carcinoma of the bladder, lipid cell variant: clinicopathologic findings and LOH analysis.
Lopez-Beltran A; Amin MB; Oliveira PS; Montironi R; Algaba F; McKenney JK; de Torres I; Mazerolles C; Wang M; Cheng L
Am J Surg Pathol; 2010 Mar; 34(3):371-6. PubMed ID: 20139762
[TBL] [Abstract][Full Text] [Related]
57. Bladder cancer in Sri Lanka: experience from a tertiary referral center.
Goonewardena SA; De Silva WA; De Silva MV
Int J Urol; 2004 Nov; 11(11):969-72. PubMed ID: 15509199
[TBL] [Abstract][Full Text] [Related]
58. Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome.
Herr HW
J Urol; 2000 Jan; 163(1):60-1; discussion 61-2. PubMed ID: 10604314
[TBL] [Abstract][Full Text] [Related]
59. Proliferative status is a risk index for recurrence in primary superficial (pTa/T1) low-grade urothelial bladder carcinoma.
Su JS; Arima K; Hasegawa M; Franco OE; Yanagawa M; Sugimura Y; Kawamura J
Hinyokika Kiyo; 2003 Nov; 49(11):649-58. PubMed ID: 14719452
[TBL] [Abstract][Full Text] [Related]
60. A review of bovine urothelial tumours and tumour-like lesions of the urinary bladder.
Roperto S; Borzacchiello G; Brun R; Leonardi L; Maiolino P; Martano M; Paciello O; Papparella S; Restucci B; Russo V; Salvatore G; Urraro C; Roperto F
J Comp Pathol; 2010; 142(2-3):95-108. PubMed ID: 19818448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
